Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $69.83 Consensus Target Price from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $69.8333.

A number of analysts have recently weighed in on the stock. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. The Goldman Sachs Group reiterated a “neutral” rating and set a $51.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 6th. HC Wainwright lifted their target price on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th.

Insider Transactions at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total value of $332,220.00. Following the completion of the sale, the chief executive officer owned 812,106 shares in the company, valued at $44,966,309.22. This trade represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William J. Phd Link sold 27,116 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the transaction, the director owned 143,332 shares in the company, valued at $8,169,924. The trade was a 15.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is owned by corporate insiders.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of TARS. Mirae Asset Global Investments Co. Ltd. grew its stake in Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after purchasing an additional 339 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after purchasing an additional 2,462 shares in the last quarter. West Wealth Group LLC acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth about $202,000. Valeo Financial Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth $209,000. Finally, Quarry LP boosted its stake in shares of Tarsus Pharmaceuticals by 20.0% in the 1st quarter. Quarry LP now owns 3,599 shares of the company’s stock valued at $185,000 after purchasing an additional 599 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Trading Up 0.5%

Shares of TARS stock opened at $72.92 on Friday. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -36.10 and a beta of 0.82. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $76.81. The stock’s 50-day moving average price is $64.34 and its 200-day moving average price is $52.07.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $118.70 million during the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. Equities research analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.